HRP20120331T1 - Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis - Google Patents
Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis Download PDFInfo
- Publication number
- HRP20120331T1 HRP20120331T1 HRP20120331TT HRP20120331T HRP20120331T1 HR P20120331 T1 HRP20120331 T1 HR P20120331T1 HR P20120331T T HRP20120331T T HR P20120331TT HR P20120331 T HRP20120331 T HR P20120331T HR P20120331 T1 HRP20120331 T1 HR P20120331T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- preparation according
- fusion protein
- seq
- nucleic acid
- Prior art date
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract 6
- 208000015181 infectious disease Diseases 0.000 title claims abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 claims abstract 12
- 102000037865 fusion proteins Human genes 0.000 claims abstract 12
- 102000039446 nucleic acids Human genes 0.000 claims abstract 9
- 108020004707 nucleic acids Proteins 0.000 claims abstract 9
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 9
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 6
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract 6
- 239000002671 adjuvant Substances 0.000 claims abstract 3
- 239000012634 fragment Substances 0.000 claims abstract 3
- 230000002163 immunogen Effects 0.000 claims abstract 3
- 230000007420 reactivation Effects 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 23
- 241000124008 Mammalia Species 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 208000032420 Latent Infection Diseases 0.000 claims 2
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 claims 2
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960003350 isoniazid Drugs 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 238000004904 shortening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67654905P | 2005-04-29 | 2005-04-29 | |
| US77701706P | 2006-02-27 | 2006-02-27 | |
| PCT/EP2006/004319 WO2006117240A2 (en) | 2005-04-29 | 2006-04-27 | Novel method for preventing or treating m tuberculosis infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120331T1 true HRP20120331T1 (hr) | 2012-05-31 |
Family
ID=36972897
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120331TT HRP20120331T1 (hr) | 2005-04-29 | 2012-04-13 | Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis |
| HRP20141125TT HRP20141125T1 (hr) | 2005-04-29 | 2014-11-19 | Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis |
| HRP20141184TT HRP20141184T1 (en) | 2005-04-29 | 2014-12-08 | Novel method for preventing or treating m. tuberculosis infection |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141125TT HRP20141125T1 (hr) | 2005-04-29 | 2014-11-19 | Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis |
| HRP20141184TT HRP20141184T1 (en) | 2005-04-29 | 2014-12-08 | Novel method for preventing or treating m. tuberculosis infection |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US8470338B2 (ru) |
| EP (3) | EP2457926B1 (ru) |
| JP (4) | JP5164830B2 (ru) |
| KR (4) | KR101352806B1 (ru) |
| CN (3) | CN102617739A (ru) |
| AT (1) | ATE543832T1 (ru) |
| AU (1) | AU2006243357B2 (ru) |
| BR (1) | BRPI0611347A2 (ru) |
| CA (2) | CA2821389C (ru) |
| CY (1) | CY1112851T1 (ru) |
| DK (3) | DK2426141T3 (ru) |
| EA (1) | EA012576B1 (ru) |
| ES (3) | ES2524572T3 (ru) |
| HR (3) | HRP20120331T1 (ru) |
| IL (2) | IL186654A (ru) |
| MA (1) | MA29678B1 (ru) |
| NO (3) | NO340766B1 (ru) |
| NZ (1) | NZ562729A (ru) |
| PH (1) | PH12013502449A1 (ru) |
| PL (3) | PL2457926T3 (ru) |
| PT (3) | PT2457926E (ru) |
| SI (3) | SI2457926T1 (ru) |
| WO (1) | WO2006117240A2 (ru) |
| ZA (1) | ZA200709209B (ru) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2457926T3 (pl) * | 2005-04-29 | 2015-03-31 | Glaxosmithkline Biologicals Sa | Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| EP2397852B1 (en) * | 2006-03-14 | 2013-12-04 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| EA021391B1 (ru) * | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
| US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
| WO2009025820A2 (en) * | 2007-08-21 | 2009-02-26 | Stc. Unm | Rationally improved isoniazid and ethionamide derivatives and activity through selective isotopic substitution |
| US20110189217A1 (en) * | 2008-06-26 | 2011-08-04 | Barry Michael A | Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance |
| KR20110049834A (ko) | 2008-07-25 | 2011-05-12 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 투베르쿨로시스 ｒｖ2386ｃ 단백질, 이를 함유하는 조성물 및 이의 용도 |
| ES2647321T3 (es) | 2008-07-25 | 2017-12-20 | Glaxosmithkline Biologicals S.A. | Composiciones y procedimientos novedosos |
| AU2009273130B2 (en) | 2008-07-25 | 2014-10-16 | Glaxo Group Limited | Novel compositions and methods |
| GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| MX370744B (es) | 2009-04-24 | 2019-12-20 | Una vacuna antituberculosis tb para evitar la reactivación. | |
| EP2528621B1 (en) | 2010-01-27 | 2016-09-21 | GlaxoSmithKline Biologicals S.A. | Modified tuberculosis antigens |
| SI2651436T1 (sl) * | 2010-12-14 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Mikrobakterijski antigenski sestavek |
| GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
| SI2661253T1 (sl) | 2011-01-04 | 2017-07-31 | Archivel Farma, Sl | Liposomska formulacija, ustrezna za zdravljenje ali preprečevanje tuberkuloze |
| GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
| WO2013090897A1 (en) * | 2011-12-15 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Using adaptive immunity to detect drug resistance |
| WO2013104943A1 (en) | 2012-01-12 | 2013-07-18 | Archivel Farma, S.L. | Mtb-c vaccine against asthma |
| HRP20240164T1 (hr) * | 2012-08-03 | 2024-04-12 | Access To Advanced Health Institute | Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama |
| WO2014047848A1 (en) * | 2012-09-27 | 2014-04-03 | Chengdu Yongan Pharmaceutical Co., Ltd. | Modified bcg strains with reduced or eliminated activity of lsr2 and pharmaceutical composition comprising same |
| CN102994595B (zh) * | 2012-11-30 | 2018-10-26 | 广州白云山拜迪生物医药有限公司 | 一种融合蛋白包涵体的制备方法 |
| CN102993266B (zh) * | 2012-11-30 | 2019-08-23 | 广州白云山拜迪生物医药有限公司 | 一种融合蛋白的纯化和复性方法 |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| US10335374B2 (en) | 2014-12-04 | 2019-07-02 | University System of Georgia, Valdosta State University | Tablet composition for anti-tuberculosis antibiotics |
| JP2018516358A (ja) * | 2015-04-02 | 2018-06-21 | バイオデシー， インコーポレイテッド | 表面選択的非線形光学技法を使用してタンパク質構造を決定するための方法 |
| US10653679B2 (en) | 2015-05-04 | 2020-05-19 | Board Of Trustees Of Michigan State University | Compositions and methods for inhibiting bacterial growth |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| BE1025160B1 (fr) | 2016-12-07 | 2018-11-26 | Glaxosmithkline Biologicals Sa | Nouveau procédé |
| US11717519B2 (en) | 2017-04-21 | 2023-08-08 | Washington University In St. Louis | Use of fatty acid oxidation inhibitors as antimicrobials |
| WO2019178472A1 (en) * | 2018-03-16 | 2019-09-19 | Washington University In St. Louis | Use of fatty acid oxidation inhibitors as antimicrobials |
| GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| TW202237116A (zh) * | 2020-12-02 | 2022-10-01 | 日商塩野義製藥股份有限公司 | 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物 |
| IL310667A (en) | 2021-08-31 | 2024-04-01 | Vir Biotechnology Inc | Tuberculosis vaccines |
| KR102534846B1 (ko) | 2021-12-14 | 2023-05-19 | 재단법인 환동해산업연구원 | 결핵균에 항균 활성을 가지는 해조류 추출물 |
| CN116162141B (zh) * | 2022-11-30 | 2024-04-12 | 中国疾病预防控制中心传染病预防控制所 | 一种结核分枝杆菌抗原epcra013及其应用 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| CA1340522C (en) | 1987-03-10 | 1999-05-04 | Heinz Dobeli | Fusion proteins containing neighbouring histidines for improved purification |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| WO1989006280A1 (en) | 1988-01-04 | 1989-07-13 | E.I. Du Pont De Nemours And Company | Multiple stage affinity process for isolation of specific cells from a cell mixture |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5215926A (en) | 1988-06-03 | 1993-06-01 | Cellpro, Inc. | Procedure for designing efficient affinity cell separation processes |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| KR920007887B1 (ko) | 1989-08-29 | 1992-09-18 | 스즈키 지도오샤 고오교오 가부시키가이샤 | 내연기관의 배기가스 정화장치 |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| WO1991016116A1 (en) | 1990-04-23 | 1991-10-31 | Cellpro Incorporated | Immunoselection device and method |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| DK0553288T3 (da) | 1990-10-18 | 1997-12-29 | Cellpro Inc | Apparat og fremgangsmåde til udskillelse af partikler ved brug af en eftergivende beholder |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| EP0877085A1 (en) | 1991-08-15 | 1998-11-11 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines |
| US5240856A (en) | 1991-10-23 | 1993-08-31 | Cellpro Incorporated | Apparatus for cell separation |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| DK0641192T3 (da) | 1992-05-18 | 1998-03-02 | Minnesota Mining & Mfg | Anordning til transmucosal lægemiddelafgivelse |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| DK0678034T3 (da) | 1993-01-11 | 1999-11-08 | Dana Farber Cancer Inst Inc | Induktion af cytotoksiske T-lymfocytreaktioner |
| FR2702160B1 (fr) | 1993-03-02 | 1995-06-02 | Biovecteurs As | Vecteurs particulaires synthétiques et procédé de préparation. |
| PL178578B1 (pl) | 1993-03-23 | 2000-05-31 | Smithkline Beecham Biolog | Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania |
| FR2704145B1 (fr) | 1993-04-21 | 1995-07-21 | Pasteur Institut | Vecteur particulaire et composition pharmaceutique le contenant. |
| US5955077A (en) | 1993-07-02 | 1999-09-21 | Statens Seruminstitut | Tuberculosis vaccine |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5551622A (en) | 1994-07-13 | 1996-09-03 | Yoon; Inbae | Surgical stapler |
| DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
| FR2723849B1 (fr) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| UA56132C2 (ru) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины |
| CA2220530A1 (en) | 1995-06-02 | 1996-12-05 | Incyte Pharmaceuticals, Inc. | Improved method for obtaining full-length cdna sequences |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US6290969B1 (en) | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| AU7158796A (en) | 1995-09-01 | 1997-03-27 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| ATE426025T1 (de) | 1995-09-01 | 2009-04-15 | Corixa Corp | Verbindungen und verfahren zur immuntherapie und diagnose von tuberkulose |
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| IL129389A0 (en) | 1996-10-11 | 2000-02-17 | Corixa Corp | Compounds and methods for diagnsosis of tuberculosis |
| US5655998A (en) | 1996-12-03 | 1997-08-12 | Yu; Chih-An | Space walking exerciser |
| EP0971739B1 (en) | 1997-04-01 | 2004-10-06 | Corixa Corporation | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| PT1584685E (pt) | 1998-02-05 | 2011-06-17 | Glaxosmithkline Biolog Sa | Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação |
| KR100797876B1 (ko) | 1998-04-07 | 2008-01-24 | 코릭사 코포레이션 | 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도 |
| WO2001024820A1 (en) | 1999-10-07 | 2001-04-12 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US7472098B2 (en) | 2000-02-14 | 2008-12-30 | Ubs Financial Services, Inc. | System and method for execution of trades made pursuant to stock option and purchase plans |
| WO2001098460A2 (en) * | 2000-06-20 | 2001-12-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US20030143240A1 (en) | 2000-06-27 | 2003-07-31 | Cabezon-Silva Teresa Elisa Virginia | Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen |
| WO2002072792A2 (en) * | 2001-03-13 | 2002-09-19 | Corixa Corporation | Heterologous fusion protein constructs comprising a leishmania antigen |
| CN100509912C (zh) | 2002-02-14 | 2009-07-08 | 三井化学株式会社 | 聚酯制备用催化剂、用此催化剂制备聚酯树脂的方法 |
| WO2003070187A2 (en) * | 2002-02-15 | 2003-08-28 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| GB0411411D0 (en) | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
| WO2006078760A1 (en) | 2005-01-19 | 2006-07-27 | Panduit Corp. | Communication channels with suppression cores |
| PL2457926T3 (pl) * | 2005-04-29 | 2015-03-31 | Glaxosmithkline Biologicals Sa | Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis |
| JP4468858B2 (ja) | 2005-06-01 | 2010-05-26 | オリンパスイメージング株式会社 | データ符号化装置、データ符号化方法、プログラム |
| US7296798B2 (en) | 2006-01-31 | 2007-11-20 | Matt Overfield | Gameboard, games played on board and methods of play requiring strategy and luck |
| MX370744B (es) | 2009-04-24 | 2019-12-20 | Una vacuna antituberculosis tb para evitar la reactivación. | |
| EP2457018A4 (en) | 2009-07-21 | 2014-10-15 | Cooper Technologies Co | CONNECTING A LIGHT EMITTING DIODE MODULE (LED) TO A THERMAL DISSIPATING ASSEMBLY, LIGHT REFLECTOR, AND ELECTRIC CIRCUITS |
| SI2651436T1 (sl) | 2010-12-14 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Mikrobakterijski antigenski sestavek |
| US9119754B2 (en) | 2011-10-08 | 2015-09-01 | Michael Dennis | Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure |
| US9051890B2 (en) | 2013-10-28 | 2015-06-09 | Ford Global Technologies, Llc | Method for estimating charge air cooler condensation storage with an intake oxygen sensor |
| US9903268B2 (en) | 2015-04-02 | 2018-02-27 | Ford Global Technologies, Llc | Internal combustion engine with two-stage supercharging capability and with exhaust-gas aftertreatment arrangement, and method for operating an internal combustion engine |
| US9810514B2 (en) | 2015-09-08 | 2017-11-07 | Deufol Sunman Inc. | Ammunition carrier consumer package |
-
2006
- 2006-04-27 PL PL11190080T patent/PL2457926T3/pl unknown
- 2006-04-27 KR KR1020077027885A patent/KR101352806B1/ko not_active IP Right Cessation
- 2006-04-27 ES ES11190080.9T patent/ES2524572T3/es active Active
- 2006-04-27 PL PL06753523T patent/PL1877426T3/pl unknown
- 2006-04-27 ES ES06753523T patent/ES2381492T3/es active Active
- 2006-04-27 DK DK11190079.1T patent/DK2426141T3/da active
- 2006-04-27 PT PT111900809T patent/PT2457926E/pt unknown
- 2006-04-27 ES ES11190079.1T patent/ES2524570T3/es active Active
- 2006-04-27 EP EP11190080.9A patent/EP2457926B1/en active Active
- 2006-04-27 CA CA2821389A patent/CA2821389C/en not_active Expired - Fee Related
- 2006-04-27 AT AT06753523T patent/ATE543832T1/de active
- 2006-04-27 KR KR1020137024859A patent/KR20130110233A/ko active Search and Examination
- 2006-04-27 CN CN2011102974226A patent/CN102617739A/zh active Pending
- 2006-04-27 NZ NZ562729A patent/NZ562729A/en not_active IP Right Cessation
- 2006-04-27 DK DK11190080.9T patent/DK2457926T3/da active
- 2006-04-27 SI SI200631870T patent/SI2457926T1/sl unknown
- 2006-04-27 SI SI200631856T patent/SI2426141T1/sl unknown
- 2006-04-27 JP JP2008508169A patent/JP5164830B2/ja not_active Expired - Fee Related
- 2006-04-27 CN CN200680023551.3A patent/CN101273055B/zh not_active Expired - Fee Related
- 2006-04-27 PT PT111900791T patent/PT2426141E/pt unknown
- 2006-04-27 EA EA200702081A patent/EA012576B1/ru not_active IP Right Cessation
- 2006-04-27 WO PCT/EP2006/004319 patent/WO2006117240A2/en active Application Filing
- 2006-04-27 CN CN201610085598.8A patent/CN106390108B/zh not_active Expired - Fee Related
- 2006-04-27 BR BRPI0611347-8A patent/BRPI0611347A2/pt active Search and Examination
- 2006-04-27 EP EP06753523A patent/EP1877426B1/en active Active
- 2006-04-27 EP EP11190079.1A patent/EP2426141B1/en active Active
- 2006-04-27 DK DK06753523.7T patent/DK1877426T3/da active
- 2006-04-27 SI SI200631315T patent/SI1877426T1/sl unknown
- 2006-04-27 CA CA2607715A patent/CA2607715C/en not_active Expired - Fee Related
- 2006-04-27 US US11/912,730 patent/US8470338B2/en not_active Expired - Fee Related
- 2006-04-27 PL PL11190079T patent/PL2426141T3/pl unknown
- 2006-04-27 KR KR20157004060A patent/KR20150036658A/ko not_active Application Discontinuation
- 2006-04-27 PT PT06753523T patent/PT1877426E/pt unknown
- 2006-04-27 KR KR1020127008426A patent/KR20120089475A/ko not_active Application Discontinuation
- 2006-04-27 AU AU2006243357A patent/AU2006243357B2/en not_active Ceased
-
2007
- 2007-10-11 NO NO20075201A patent/NO340766B1/no not_active IP Right Cessation
- 2007-10-15 IL IL186654A patent/IL186654A/en not_active IP Right Cessation
- 2007-10-25 MA MA30313A patent/MA29678B1/fr unknown
- 2007-10-25 ZA ZA2007/09209A patent/ZA200709209B/en unknown
-
2011
- 2011-09-13 IL IL215112A patent/IL215112A/en not_active IP Right Cessation
- 2011-09-22 JP JP2011207361A patent/JP2012065650A/ja active Pending
-
2012
- 2012-03-28 NO NO20120381A patent/NO340206B1/no not_active IP Right Cessation
- 2012-04-13 HR HRP20120331TT patent/HRP20120331T1/hr unknown
- 2012-04-24 CY CY20121100382T patent/CY1112851T1/el unknown
- 2012-10-12 JP JP2012227192A patent/JP5659207B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-16 US US13/895,574 patent/US9056913B2/en not_active Expired - Fee Related
- 2013-11-26 PH PH12013502449A patent/PH12013502449A1/en unknown
-
2014
- 2014-09-24 NO NO20141158A patent/NO345071B1/no not_active IP Right Cessation
- 2014-10-24 JP JP2014217282A patent/JP2015057403A/ja active Pending
- 2014-11-19 HR HRP20141125TT patent/HRP20141125T1/hr unknown
- 2014-12-08 HR HRP20141184TT patent/HRP20141184T1/hr unknown
-
2015
- 2015-01-23 US US14/603,935 patent/US9655958B2/en not_active Expired - Fee Related
-
2017
- 2017-03-20 US US15/463,557 patent/US10105430B2/en not_active Expired - Fee Related
-
2018
- 2018-09-19 US US16/135,553 patent/US10350283B2/en not_active Expired - Fee Related
-
2019
- 2019-06-25 US US16/451,040 patent/US10639361B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120331T1 (hr) | Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis | |
| JP2008539187A5 (ru) | ||
| Lambert et al. | Can successful vaccines teach us how to induce efficient protective immune responses? | |
| ES2714383T3 (es) | Vacuna TB contra la tuberculosis para impedir la reactivación | |
| Harro et al. | The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies | |
| Nadel | Prospects for eradication of meningococcal disease | |
| Ruggiero et al. | The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? | |
| JP2008543890A5 (ru) | ||
| EP2270174A1 (en) | Combination neisserial compositions | |
| Bergfors et al. | Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses | |
| TWI630915B (zh) | 無細胞百日咳疫苗 | |
| Kuhdari et al. | Meningococcal B vaccination: real-world experience and future perspectives | |
| Ma et al. | Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre-and post-exposure infections by driving Th1-type T cell immunity | |
| Tanghe et al. | Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting | |
| Osterloh | The neglected challenge: Vaccination against rickettsiae | |
| Kaaijk et al. | Routine vaccination against MenB: considerations for implementation | |
| JP2017511327A5 (ru) | ||
| US20140161836A1 (en) | Carious tooth vaccine and preparation method | |
| Wicher et al. | Immunization of guinea pigs with recombinant TmpB antigen induces protection against challenge infection with Treponema pallidum Nichols | |
| Yang et al. | Protection against Staphylococcus aureus and tetanus infections by a combined vaccine containing SasA and TeNT‑Hc in mice | |
| CA2598078A1 (en) | Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis | |
| Pasteur et al. | The effects of inadvertent intramuscular injection of BCG vaccine | |
| EP2501396A1 (en) | LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE | |
| JP2010516279A (ja) | 表皮ブドウ球菌に対する防御免疫応答を誘導するためのポリペプチド | |
| Hovav et al. | Pseudo-rationale design of efficient TB vaccines: lesson from the mycobacterial 27-kDa lipoprotein |